US launches Section 301 probe of Germany over pharmaceutical pricing

The US has initiated a Section 301 probe into Germany, citing persistent underpayment for innovative pharmaceutical products. This tariff investigation establishes a foundation for potential levies on German goods as retaliation. Such actions could significantly strain transatlantic trade relations and create a precedent for future global pharmaceutical disputes. The probe focuses on pricing mechanisms that the US deems unfair, signaling a shift toward more aggressive trade enforcement within the pharmaceutical sector to protect innovative product value.